Washington, D.C. 20549






Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): September 25, 2019


Emmaus Life Sciences, Inc.

(Exact name of registrant as specified in its charter)


Delaware   001-35527   87-0419387

(State or other jurisdiction

of incorporation)

  (Commission File Number)  

(I.R.S. Employer

Identification No.)


21250 Hawthorne Boulevard, Suite 800, Torrance, CA   90503
(Address of principal executive offices)   (Zip Code)


Registrant’s telephone number, including area code (310) 214-0065


(Former name or former address, if changed, since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))


Securities registered pursuant to Section 12(b) of the Act: 


Title of each class   Trading Symbol   Name of each exchange
on which registered
Common Stock, $0.001 par value   EMMA   OTCQB
Common Stock Purchase Warrants   EMMAW   OTC Pink


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ☒


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐








Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year


Change in Fiscal Year


As previously reported, in July 2019 Emmaus Life Sciences, Inc. (“we,” “our,” “us,” “Emmaus” or the “company”) acquired EMI Holding, Inc., our wholly owned subsidiary, by way of a reverse merger transaction in which EMI Holding, Inc. is treated as the acquirer for financial accounting purposes. On September 25, 2019, therefore, our board of directors approved a change in our fiscal year end from September 30 to December 31, the fiscal year end of EMI Holding, Inc.


In accordance with SEC guidance, no transition report is required in connection with the change in our fiscal year end. Accordingly, we intend to file a Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 and subsequently file our Annual Report on Form 10-K for the year ending December 31, 2019.







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: September 30, 2019 Emmaus Life Sciences, Inc.
    Name: Joseph C. Sherwood III
    Title:   Chief Financial Officer